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Abstract (Word count: 247) 
Background: The prevalence of and factors associated with uncontrolled hypertension and 
apparent resistant hypertension were assessed in the European Study on Cardiovascular Risk 
Prevention and Management in Usual Daily Practice (EURIKA; NCT00882336). 
Methods: EURIKA was a cross-sectional observational study including patients being 
treated for the primary prevention of cardiovascular disease in 12 European countries. 
Patients were assessed if they were being treated for hypertension (N = 5220). Blood pressure 
control was defined according to European guidelines, with sensitivity analysis taking 
account of patients’ age and diabetes status. Associated factors were assessed using 
multivariate analysis. 
Results: In the primary analysis, a total of 2691 patients (51.6%) had uncontrolled 
hypertension. Factors significantly associated with an increased risk of having uncontrolled 
hypertension included female sex (odds ratio [OR]: 2.29; 95% confidence interval [CI]: 1.93–
2.73), body mass index (BMI; OR per kg/m
2
: 1.03; 95% CI: 1.01–1.04), and geographic 
location. A total of 749 patients (14.3%) had apparent resistant hypertension. Factors 
significantly associated with an increased risk of having apparent resistant hypertension 
included BMI (OR per kg/m
2
: 1.06; 95% CI: 1.04–1.08), diabetes (OR: 1.28; 95% CI: 1.06–
1.53), use of statins (OR: 1.36; 95% CI: 1.15–1.62), serum uric acid levels (OR: 1.16; 95% 
CI: 1.09–1.23), and geographic location. Similar results were seen in sensitivity analyses. 
Conclusions: Over 50% of patients treated for hypertension continued to have uncontrolled 
blood pressure, and 14.3% had apparent resistant hypertension. Positive associations were 
seen with other cardiovascular risk factors. 
 
Keywords: Hypertension; cardiovascular disease; observational study; primary prevention; 
risk factor. 
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Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index; CI, 
confidence interval; CVD, cardiovascular disease; DBP, diastolic blood pressure; ESC, 
European Society of Cardiology; ESH, European Society of Hypertension; EURIKA, 
European Study on Cardiovascular Risk Prevention and Management in Usual Daily 
Practice; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-
C, low-density lipoprotein cholesterol; OR, odds ratio; SCORE, Systematic Coronary Risk 
Evaluation; SBP, systolic blood pressure; SD, standard deviation. 
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1. Introduction 
Despite recent reductions in rates of mortality from cardiovascular disease (CVD) throughout 
Europe, CVD remains responsible for approximately 47% of all deaths across the continent 
each year [1]. Primary and secondary prevention of CVD, therefore, remains of great 
importance. Principal risk factors for having a first cardiovascular event include age, sex, 
smoking, arterial hypertension, dyslipidaemia, diabetes, obesity, and physical inactivity [2]. 
Control of modifiable risk factors remains poor: the most recent European CVD statistics 
report that the prevalence of elevated blood pressure in adults aged 25 years or over ranges 
between 33.6% (Israel) and 48.3% (Ukraine), whereas the prevalence of dyslipidaemia in the 
same population ranges between 24.0% (Tajikistan) and 69.8% (Iceland)  [1]. 
 
Recently, we conducted the European Study on Cardiovascular Risk Prevention and 
Management in Usual Daily Practice (EURIKA; ClinicalTrials.gov identifier: 
NCT00882336), a study of the management of cardiovascular risk factors in primary care in 
12 European countries [3]. Included patients were aged 50 years or over and had at least one 
risk factor for CVD but no history of cardiovascular events. As part of this study, we have 
previously reported that control of blood pressure among patients with hypertension in 
Europe is approximately 38.8%, whereas control of blood serum cholesterol levels among 
patients with dyslipidaemia is approximately 43.3% [4]. In the present paper, we describe in 
detail the prevalence of uncontrolled hypertension and of apparent resistant hypertension 
among patients being treated for hypertension in the EURIKA population. Factors associated 
with uncontrolled hypertension and with apparent resistant hypertension were also assessed. 
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2. Methods 
 
2.1 Study design and participants 
EURIKA was carried out in 12 European countries (Austria, Belgium, France, Germany, 
Greece, Norway, Russia, Spain, Sweden, Switzerland, Turkey, and the UK) [4]. Data 
collection started in May 2009 and ended in January 2010, with a 3-month data collection 
period for each country. The study protocol was approved by the appropriate clinical research 
ethics committees in each participating country, and all patients provided signed informed 
consent. 
 
The methods for the study have been reported in detail elsewhere [3]. Briefly, the study 
sample was selected in a two-stage process that involved the random selection of both 
physicians and their patients [3, 5]. In the first stage, primary care practitioners and 
specialists involved in CVD prevention (including cardiologists, endocrinologists, and 
internal medicine specialists) were randomly selected to be invited to participate using the 
OneKey database (Cegedim Dendrite, Boulogne-Billancourt, France) [6]. In total, 809 
physicians (approximately 60 per country) agreed to participate in EURIKA, 64% of whom 
were primary care practitioners [5]. In the second stage, participating physicians sequentially 
invited patients who met the selection criteria (aged 50 years or older, free of CVD but 
having at least one major cardiovascular risk factor [dyslipidaemia, hypertension, smoking, 
diabetes mellitus, or obesity]) [4]. Approximately 600 patients were included per country, 
with a final population size of 7641. For the present analysis, included patients were those 
who were receiving an antihypertensive medication and for whom blood pressure 
measurements were included in the database (N = 5220). 
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2.2 Assessment of CVD risk factors 
Demographic information and other details of participating patients were gathered from 
medical records and patient interviews. For each patient, a physical examination was 
conducted, blood pressure was measured, and a 12-h fasting blood sample was collected 
within 1 day of the initial outpatient consultation [3]. Blood pressure was determined in 
standardised conditions, using calibrated mercury sphygmomanometers or validated 
automated devices, and appropriate-size cuffs [2, 3, 7]. The mean of three readings was used 
for analyses. 
 
Blood sample analysis was carried out at a central laboratory (Bio Analytical Research 
Corporation, Ghent, Belgium), with the exception of samples from patients in Russia 
(approximately 5% of the total patient population), for whom laboratory analysis was carried 
out locally. High-density lipoprotein cholesterol (HDL-C) concentration was measured by a 
modified enzymatic method, total cholesterol concentration by the CHOD-PAP method, and 
triglyceride concentration by the GPO-PAP method (all using the Roche Modular P 
chemistry analyser; Roche Diagnostics, Indianapolis, IN, USA). Low-density lipoprotein 
cholesterol (LDL-C) concentration was calculated by the Friedewald formula [8]. Ten-year 
CVD-related mortality risk for each patient was estimated using the Systematic Coronary 
Risk Evaluation (SCORE) algorithms for high-risk and low-risk countries, as appropriate [9]. 
 
2.3 Control of hypertension 
In the primary analysis of uncontrolled hypertension, control of blood pressure was defined in 
all patients as systolic blood pressure (SBP) <140 mmHg and diastolic blood pressure 
(DBP) <90 mmHg, in line with the 2007 European Society of Hypertension (ESH)/European 
Society of Cardiology (ESC) guidelines in place at the time the study was carried out [10]. In 
a sensitivity analysis, this definition was altered to consider patients’ age and diabetes status, 
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in line with the 2007 ESH/ ESC guidelines [7]. In this sensitivity analysis, control of blood 
pressure was defined as SBP <150 mmHg and DBP <90 mmHg for patients aged 80 years or 
over regardless of diabetes status, SBP <140 mmHg and DBP <85 mmHg for patients aged 
under 80 years with diabetes, and SBP <140 mmHg and DBP <90 mmHg for all other 
patients. Apparent resistant hypertension was defined as having uncontrolled hypertension 
(primary and sensitivity analysis definitions as given above) despite being treated with at 
least three antihypertensive drugs including a diuretic, or having controlled hypertension 
while being treated with four or more antihypertensive drugs [7]. 
 
2.4 Statistical methods 
Data are presented as mean and standard deviation for continuous variables, and as frequency 
and percentage for categorical variables. Comparisons between groups were performed using 
Student’s t-tests for normally distributed continuous variables, Mann-Whitney U-tests for 
continuous variables that were not normally distributed, and χ2 or Fisher’s exact tests for 
categorical variables, as appropriate 
 
Factors associated with uncontrolled hypertension were assessed in the subpopulation of 
patients receiving one or two antihypertensive medications, using univariate and 
subsequently multivariate logistic regression models and using both the primary and 
sensitivity analysis definitions of blood pressure control. Variables included in the 
multivariate analyses were country, age, sex, body mass index (BMI), diabetes status, 
tobacco use, LDL-C levels, frequency of healthcare visits, use of statins, serum uric acid 
level, and overall cardiovascular risk calculated according to SCORE. A stepwise selection 
model was used to keep only those variables statistically significantly associated at the 5% 
significance level in the final model. Factors associated with apparent resistant hypertension 
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were assessed using the same methods in the overall population. Statistical analyses were 
carried out using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). 
 
3. Results 
3.1 Patient characteristics and factors associated with uncontrolled hypertension 
Of the 7641 patients included in EURIKA, 5220 were treated for hypertension and had blood 
pressure measurements available in the database, and were therefore included in the analysis. 
The mean age was 64.5 years, and 47.9% were men (Table 1). A total of 29.3% had diabetes, 
and the mean BMI was 29.6 kg/m
2
.  
 
In the primary analysis, 2691 patients (51.6%) had uncontrolled hypertension (Fig. 1). In the 
sensitivity analysis, using different definitions of blood pressure control according to 
patients’ age and diabetes status, the number of patients with uncontrolled hypertension 
increased slightly to 2721 (52.1%) (Fig. 1). In the primary analysis, the prevalence of 
uncontrolled hypertension varied according to country, ranging from 38.6% in Greece to 
59.7% in Turkey (Supplementary Table 1). A similar between-country range was observed in 
the sensitivity analysis (40.5–60.7%) (Supplementary Table 2). In both the primary and 
sensitivity analyses, the characteristics of patients with controlled and uncontrolled 
hypertension were broadly similar (Table 1, Supplementary Table 3). Patients with 
uncontrolled hypertension had greater numbers of metabolic syndrome markers and a higher 
overall cardiovascular risk according to SCORE. The most commonly used antihypertensive 
drugs, either alone or in combination, were diuretics, followed by angiotensin II receptor 
blockers, angiotensin-converting enzyme inhibitors, beta-blocking agents, and calcium 
channel blockers. In the primary analysis, a total of 2012 patients (74.8%) with uncontrolled 
hypertension were receiving only one or two antihypertensive medications. In the sensitivity 
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analysis, the proportion of patients with uncontrolled hypertension receiving only one or two 
antihypertensive medications was 74.4%. 
 
To investigate factors associated with uncontrolled hypertension, multivariate analysis was 
carried out comparing patients with and without uncontrolled hypertension who were 
receiving only one or two antihypertensive medications. In the primary analysis, patients 
from Spain and Switzerland were found to be statistically significantly more likely to have 
uncontrolled hypertension than patients in the UK (Fig. 2). Female sex and BMI were found 
to be significantly positively associated with having uncontrolled hypertension. Conversely, 
age, being a current or former smoker, or receiving a statin were found to be significantly 
negatively associated with having uncontrolled hypertension. Higher overall 10-year risk of 
cardiovascular mortality calculated according to SCORE was also significantly associated 
with uncontrolled hypertension. Similar factors were found to be associated with uncontrolled 
hypertension in the sensitivity analysis; in addition to those factors listed above, being from 
Belgium, relative to the UK, and having diabetes were both associated with having 
uncontrolled hypertension (Supplementary Fig. 1). 
 
3.2 Factors associated with apparent resistant hypertension 
Of the total patient population, 749 (14.3%) had apparent resistant hypertension in the 
primary analysis at the time the study was carried out (Fig. 1, Table 1). In the sensitivity 
analysis, the proportion was similar, with 764 patients having resistant hypertension (14.6%). 
The characteristics of patients with and without apparent resistant hypertension in the primary 
and sensitivity analyses are shown in Table 1 and Supplementary Table 3, respectively. In the 
primary analysis, the prevalence of apparent resistant hypertension varied according to 
country, ranging from 9.9% in France to 25.5% in Germany (Supplementary Table 1). A 
similar range was seen in the sensitivity analysis (Supplementary Table 2). Diabetes was 
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more prevalent in the population of patients with apparent resistant hypertension compared 
with patients without apparent resistant hypertension (39.4% vs. 27.6%).  
 
Multivariate analysis was carried out comparing patients with and without apparent resistant 
hypertension. In the primary analysis, patients from France, Spain, and Switzerland were 
statistically significantly less likely to have apparent resistant hypertension than patients from 
the UK, whereas patients from Germany were more likely to have apparent resistant 
hypertension than patients from the UK (Fig. 3). BMI, diabetes, use of statins, and serum uric 
acid levels were significantly positively associated with apparent resistant hypertension, 
whereas being a current smoker was significantly negatively associated with apparent 
resistant hypertension. Similarly to uncontrolled hypertension, higher overall cardiovascular 
risk according to SCORE was significantly associated with apparent resistant hypertension. 
Similar factors were found to be associated with apparent resistant hypertension in the 
sensitivity analysis, but statistical significance was lost for the difference between patients 
from France, Spain, and Switzerland relative to patients from the UK (Supplementary Fig. 2). 
 
4. Discussion 
Here, we have analysed factors associated with uncontrolled hypertension and with apparent 
resistant hypertension in a European population of patients being treated for hypertension, 
using data from the large, international EURIKA study. Two definitions of control of blood 
pressure were used: in the primary analysis, SBP <140 mmHg and DBP <90 mmHg for all 
patients according to the 2007 ESH/ESC guidelines in place at the time the study was carried 
out [10], and in the sensitivity analysis an altered definition taking account of patients’ age 
and diabetes status, according to the 2013 ESH/ESC guidelines [7]. To our knowledge, this is 
the first time such an analysis has been carried out using the 2013 guidelines.  
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Similar results were seen for both the primary and sensitivity analyses of uncontrolled 
hypertension: in both, over 50% of patients treated for hypertension continued to have 
uncontrolled blood pressure at the time the survey was carried out. These results are 
particularly relevant in light of the recent findings from the Systolic Blood Pressure 
Intervention Trial (SPRINT), showing that intensive treatment of hypertension to a target of 
SBP <120 mmHg results in better clinical outcomes than treatment to a target of 
SBP <140 mmHg, in high-risk hypertensive patients without diabetes [11]. Considerable 
variability was seen between different countries, with the prevalence of uncontrolled 
hypertension ranging from approximately 40% to approximately 60%. This indicates that in 
some regions treatment of patients with hypertension could be improved in order to achieve 
performance in line with other European countries. Almost 75% of patients with uncontrolled 
hypertension were receiving only one or two antihypertensive drugs; if tolerated there is the 
potential to intensify their therapy in order to increase the chance of bringing their blood 
pressure down to target levels. In patients receiving multiple antihypertensive medications, 
poor control of hypertension supports the possibility of improvements in drug combination 
choices and in the doses of medications used. 
 
In the multivariate analysis of uncontrolled hypertension in patients receiving one or two 
antihypertensive medications, age, being a current or former smoker, and receiving a statin 
were found to be negatively associated with uncontrolled hypertension, whereas female sex, 
BMI, and SCORE were found to be positively associated with uncontrolled hypertension, 
with the addition of diabetes in the sensitivity analysis. These findings are partially in line 
with risk factors for the development of hypertension identified in the general population, 
which include obesity and diabetes [7]. The association with SCORE is expected, as 
hypertension contributes to overall cardiovascular risk. However, some findings were 
unexpected. Counterintuitive associations, including the negative associations of age, 
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smoking, and statin treatment with uncontrolled hypertension, are unlikely to be clinically 
relevant and could result from confounding by indication. For example, the negative 
association between age and uncontrolled hypertension could be because more aggressive 
treatment of hypertension is used in older patients. The presence of the associated factors 
identified here, and other cardiovascular risk factors, should be considered by physicians 
when making a decision about the intensity of treatment to be prescribed to individual 
patients with elevated blood pressure, and treatment of all cardiovascular risk factors will 
reduce overall cardiovascular risk. 
 
Also of interest is the high proportion of patients with greater numbers of metabolic 
syndrome markers among patients with uncontrolled hypertension relative to patients with 
controlled hypertension. Although this variable was not included in the multivariate analysis 
owing to collinearity, in univariate analysis the association was found to be statistically 
significant when comparing patients with fewer than three metabolic syndrome markers with 
those with three or more metabolic syndrome markers (data not shown; p = 0.001). Several 
previous studies, including the Tromsø and Brisighella Heart Studies [12, 13], have shown an 
association between hypertension and elevated serum lipid levels. Pathophysiological 
mechanisms for this association, including overexpression of angiotensin II type 1 receptors 
and up-regulation of angiotensin II production as a result of elevated serum lipid levels or 
hyperinsulinemia, have been suggested [14-20]. Although our multivariate analysis failed to 
demonstrate an association between uncontrolled hypertension and LDL-C levels, it is 
nevertheless important to manage all cardiovascular risk factors in patients in whom 
hypertension is associated with abnormalities in metabolic profile and lipid levels. 
 
A total of 14.3% of the EURIKA population being treated for hypertension were found to 
have apparent resistant hypertension at the time of the study (14.6% in the sensitivity 
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analysis), with proportions among the countries ranging from 9.9% to 25.5%. These patients 
may be at particularly high risk of cardiovascular and renal events [7, 21-24]. Previous 
studies have shown that resistant hypertension is associated with younger age, male sex, 
duration of hypertension, obesity, kidney and cardiac damage, and overall cardiovascular risk 
profile [22, 25]. In line with this, factors we found to be positively associated with apparent 
resistant hypertension included diabetes, BMI, and serum uric acid levels. The clinical 
relevance of other findings is less clear: counterintuitively, we found that current smokers 
were less likely to have apparent resistant hypertension than people who had never smoked. 
Potentially, this is due to lifestyle modification in the group of patients with apparent resistant 
hypertension. We also found that apparent resistant hypertension was more likely in some 
European countries than in others, and was positively associated with the use of statins. The 
association with the use of statins may be indicative of more intensive treatment of 
cardiovascular risk factors generally among patients with apparent resistant hypertension, and 
the differing likelihood of uncontrolled or apparent resistant hypertension in some countries 
versus others may reflect country-specific differences in lifestyle factors and treatment 
practices that could not be accounted for in the multivariate analysis. 
 
A particular strength of our study was that it included a large sample of patients from 12 
different countries, tested according to standardised procedures. As patients were randomly 
chosen to participate (acceptance rate: 62.1%), the study population is representative of the 
general population in each country. 
 
4.1 Study limitations 
Limitations of our study include the fact that the data-collection period for each country was 
only 3 months, so it is possible that frequent healthcare service users were overrepresented in 
the study cohort. This may bias the patient population towards the inclusion of less healthy 
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patients. The nature of the cross-sectional study does not allow apparent resistant 
hypertension to be distinguished from clinical resistant hypertension. It is also difficult to 
distinguish factors that have a causative association with uncontrolled hypertension or 
apparent resistant hypertension from those associated with suboptimal therapeutic approaches 
to the disease. Finally, despite the large numbers of included patients and the identification of 
factors significantly associated with uncontrolled hypertension and with apparent resistant 
hypertension in multivariate analysis, the numeric differences in the distribution of associated 
factors between patients with or without uncontrolled hypertension or apparent resistant 
hypertension were often small. 
 
4.2 Conclusion 
We conclude that, in a large proportion of patients being treated for hypertension, blood 
pressure remains poorly controlled. There is also a high prevalence of apparent resistant 
hypertension. Intensification or change of treatment in such patients is necessary in order to 
reduce their overall cardiovascular risk. More effective control of other factors associated 
with poor blood pressure control will also contribute to reducing total cardiovascular risk. 
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Tables and figures 
 
Fig. 1. Proportion of patients with uncontrolled hypertension and apparent resistant 
hypertension in the primary and sensitivity analyses. 
 
Fig. 2. Multivariate analysis of factors associated with uncontrolled hypertension (primary 
analysis). 
a
Relative to the UK; 
b
per year; 
c
female, relative to male; 
d
per kg/m
2
; 
e
relative to never; 
f
relative to non-use; 
g
relative to low (<2%). 
BMI, body mass index; CI, confidence interval; OR, odds ratio; SCORE, Systematic 
Coronary Risk Evaluation. 
 
Fig. 3. Multivariate analysis of factors associated with apparent resistant hypertension 
(primary analysis). 
a
Relative to the UK; 
b
per kg/m
2
; 
c
relative to non-diabetes; 
d
relative to never; 
e
per mg/dL; 
f
relative to more than once a month; 
g
relative to non-use; 
h
relative to low (<2%). 
BMI, body mass index; CI, confidence interval; OR, odds ratio; SCORE, Systematic 
Coronary Risk Evaluation. 
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Table 1 
Patient characteristics, drug treatments, and hypertensive status (primary analysis). 
 Overall 
 
(N = 5220) 
Uncontrolled 
hypertension 
(n = 2691) 
Controlled 
hypertension 
(n = 2529) 
Apparent resistant 
hypertension 
(n = 749) 
Non-resistant 
hypertension 
(n = 4471) 
Age, years, mean (SD)  64.5 (9.0) 64.6 (8.9) 64.4 (9.1) 65.9 (8.9) 64.3 (9.0) 
Sex      
Male 2498 (47.9) 1299 (48.3) 1199 (47.4) 378 (50.5) 2120 (47.4) 
Female 2722 (52.1) 1392 (51.7) 1330 (52.6) 371 (49.5) 2351 (52.6) 
Smoking status      
Never 2916 (55.9) 1502 (55.8) 1414 (55.9) 432 (57.7) 2484 (55.6) 
Current 847 (16.2) 419 (15.6) 428 (16.9) 95 (12.7) 752 (16.8) 
Former 1399 (26.8) 735 (27.3) 664 (26.3) 214 (28.6) 1185 (26.5) 
Unknown 58 (1.1) 35 (1.3) 23 (0.9) 8 (1.1) 50 (1.1) 
Diabetes 1530 (29.3) 774 (28.8) 756 (29.9) 295 (39.4) 1235 (27.6) 
BMI, kg/m
2
, mean (SD) 29.6 (5.5) 29.8 (5.6) 29.3 (5.4) 31.3 (6.3) 29.3 (5.3) 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
         22 
SBP, mmHg, mean (SD) 138.3 (16.3) 149.8 (13.5) 126.0 (8.0) 146.5 (17.2) 136.9 (15.8) 
DBP, mmHg, mean (SD) 82.0 (10.0) 87.1 (9.8) 76.6 (6.9) 84.4 (11.7) 81.6 (9.6) 
Lipid levels, mmol/L, 
mean (SD) 
     
Total cholesterol 5.4 (1.1) 5.5 (1.1) 5.3 (1.1) 5.2 (1.1) 5.4 (1.1) 
LDL-C 3.1 (1.0) 3.2 (1.0) 3.0 (0.9) 3.0 (0.9) 3.2 (1.0) 
HDL-C 1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 
Triglycerides 1.8 (1.3) 1.9 (1.3) 1.8 (1.3) 2.0 (1.3) 1.8 (1.3) 
HbA1c, %, mean (SD) 6.2 (2.3) 6.3 (2.9) 6.1 (1.4) 6.4 (2.9) 6.2 (2.1) 
Number of metabolic 
syndrome markers
a
 
     
1 339 (6.5) 164 (6.1) 175 (6.9) 26 (3.5) 313 (7.0) 
2 1600 (30.7) 771 (28.7) 829 (32.8) 174 (23.2) 1426 (31.9) 
3 1543 (29.6) 806 (30.0) 737 (29.1) 246 (32.8) 1297 (29.0) 
4 1028 (19.7) 556 (20.7) 472 (18.7) 170 (22.7) 858 (19.2) 
5 469 (8.9) 249 (9.3) 220 (8.7) 98 (13.1) 371 (8.3) 
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Unknown 241 (4.6) 145 (5.4) 96 (3.8) 35 (4.7) 206 (4.6) 
SCORE risk
b
      
Low (<2%) 1138 (21.8) 393 (14.6) 745 (29.5) 107 (14.3) 1031 (23.1) 
Intermediate (2–5%) 1594 (30.5) 727 (27.0) 867 (34.3) 193 (25.8) 1401 (31.3) 
High (≥5%) 2374 (45.5) 1500 (55.7) 874 (34.6) 431 (57.5) 1943 (43.5) 
Unknown 114 (2.2) 71 (2.6) 43 (1.7) 18 (2.4) 96 (2.1) 
Lipid-lowering treatment      
None 2880 (55.2) 1584 (58.9) 1296 (51.2) 363 (48.5) 2517 (56.3) 
Statins alone 2064 (39.5) 970 (36.0) 1094 (43.3) 338 (45.1) 1726 (38.6) 
Statins with other 
treatment 
119 (2.3) 54 (2.0) 65 (2.6) 27 (3.6) 92 (2.1) 
Other treatment 
without statins 
157 (3.0) 83 (3.1) 74 (2.9) 21 (2.8) 136 (3.0) 
Use of antihypertensive 
medications 
     
Diuretics 2390 (45.8) 1224 (45.5) 1166 (46.1) 744 (99.3) 1646 (36.8) 
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Angiotensin II receptor 
blockers 
2111 (40.4) 1049 (39.0) 1062 (42.0) 413 (55.1) 1698 (38.0) 
ACE inhibitors 1905 (36.5) 1014 (37.7) 891 (35.2) 349 (46.6) 1556 (34.8) 
β-adrenergic 
antagonists 
1783 (34.2) 901 (33.5) 882 (34.9) 499 (66.6) 1284 (28.7) 
Calcium channel 
blockers 
1558 (29.8) 863 (32.1) 695 (27.5) 501 (66.9) 1057 (23.6) 
α-adrenergic 
antagonists 
166 (3.2) 94 (3.5) 72 (2.8) 84 (11.2) 82 (1.8) 
Other anti-adrenergic 
agents 
26 (0.5) 14 (0.5) 12 (0.5) 13 (1.7) 13 (0.3) 
Other 223 (4.3) 130 (4.8) 93 (3.7) 94 (12.6) 129 (2.9) 
Number of 
antihypertensive drugs 
used 
     
1 2032 (38.9) 1036 (38.5) 996 (39.4) 0 (0.0) 2032 (45.4) 
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2 1895 (36.3) 976 (36.3) 919 (36.3) 0 (0.0) 1895 (42.4) 
3 918 (17.6) 468 (17.4) 450 (17.8) 384 (51.3) 534 (11.9) 
4 303 (5.8) 167 (6.2) 136 (5.4) 294 (39.3) 9 (0.2) 
5 59 (1.1) 36 (1.3) 23 (0.9) 58 (7.7) 1 (0.0) 
6 12 (0.2) 7 (0.3) 5 (0.2) 12 (1.6) 0 (0.0) 
7 1 (0.0) 1 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 
Data are n (%) unless indicated otherwise. 
a
Low HDL-C (<1 mmol/L for men or <1.3 mmol/L for women); high triglycerides (≥1.7 mmol/L); high HbA1c (≥6%); high waist circumference 
(dependent on ethnicity); high blood pressure (SBP ≥130 mmHg and/or DBP ≥85 mmHg or being treated with an antihypertensive drug). Note that 
all patients in the analysis were being treated with an antihypertensive drug and therefore had at least one metabolic syndrome marker. 
b
10-year risk of mortality due to cardiovascular disease, based on age, sex, smoking status, SBP, and total cholesterol levels [9]. 
ACE, angiotensin-converting enzyme; BMI, body mass index; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation; 
SD, standard deviation. 
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Figure 3 
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Highlights 
 EURIKA was a cross-sectional observational study in 12 European countries 
 Uncontrolled hypertension was assessed among patients treated for hypertension 
 More than half of all treated patients continued to have uncontrolled hypertension 
 Approximately 14% had apparent resistant hypertension 
 Associations were seen between hypertension and other cardiovascular risk factors 
